ADGRF5

Across TCGA pan-cancer cohorts, ADGRF5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADGRF5 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADGRF5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADGRF5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where ADGRF5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.861	0.361	.002	20	view →
HNSC	DFS	Tertile	All	0.732	0.387	.022	4	view →
LSCC	DFS	Median	II,III,IV	0.556	0.811	.027	3	view →
CCRCC	DFS	Quartile	III,IV	0.787	0.361	.041	2	view →
PDAC	DFS	Median	All	0.150	0.374	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADGRF5–LUAD (OS)

Open the LUAD breakdown →